Hotline:+86 2884841969
Outbound Sales&Marketing

Ms.Yang 
Tel: +86 2884841969 
Mobile: +86 13876200465 (English) 
Skype/Wechat:+86 13876200465 
Email: ycling@enlaibio.com

Mr. Yang  
Tel: +86 2884871826
Mobile: +86 13908183771   
Email: yangcx@enlaibio.com
Your current location:Homepage >
\

As a first line treatment drugs for chronic lymphocytic leukemia, Ibrutinib improves survival compared with Ofatumumab in patients with previously treated Chronic Lymphocytic Leukemia.As a first line treatment drugs for chronic lymphocytic leukemia, Ibrutinib improves survival compared with Ofatumumab in patients with previously treated Chronic Lymphocytic Leukemia.

The typical cost of ibrutinib in the United States is about $148,000 a year.

In China, Ibrutinib was added to the Chinese Pharmaceutical Benefits Scheme in 2018.